(Q43656976)

25 November 2017

title

In vitro effects of E3040, a dual inhibitor of 5-lipoxygenase and thromboxane A(2) synthetase, on eicosanoid production (English)

1 reference

25 November 2017

1 reference

ChEBI release 2020-05-28

K Oketani

1

1 reference

25 November 2017

N Nagakura

series ordinal

2

1 reference

25 November 2017

K Harada

series ordinal

3

1 reference

25 November 2017

T Inoue

series ordinal

4

1 reference

25 November 2017

language of work or name

English

0 references

publication date

1 June 2001

1 reference

European Journal of Pharmacology

25 November 2017

published in

1 reference

25 November 2017

volume

422

1 reference

25 November 2017

issue

1-3

1 reference

25 November 2017

page(s)

209-216

1 reference

Measurement of in vivo rectal mucosal cytokine and eicosanoid production in ulcerative colitis using filter paper

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901022-6

OKY-1581, a potential selective thromboxane synthetase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901022-6

In vitro pharmacology of BAY X1005, a new inhibitor of leukotriene synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901022-6

Review article: the mode of action of the aminosalicylates in inflammatory bowel disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901022-6

Novel dual inhibitors of 5-lipoxygenase and thromboxane A2 synthetase: synthesis and structure-activity relationships of 3-pyridylmethyl-substituted 2-amino-6-hydroxybenzothiazole derivatives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901022-6

In vivo profiles of eicosanoids in ulcerative colitis, Crohn's colitis, and Clostridium difficile colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901022-6

Selective 5-lipoxygenase inhibition in ulcerative colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901022-6

Inhibition of nuclear factor kappa B and induction of apoptosis in T-lymphocytes by sulfasalazine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901022-6

Chemotactic activity in inflammatory bowel disease. Role of leukotriene B4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901022-6

5-Aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901022-6

Differential regulation of 5-lipoxygenase and cyclo-oxygenase pathways of arachidonate metabolism in rat peritoneal leukocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901022-6

Mediators of inflammation in chronic inflammatory bowel disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901022-6

Possible mode of action of 5-aminosalicylic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901022-6

Prostaglandins and ulcerative colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901022-6

Prostaglandin synthesis inhibitors in ulcerative colitis: Flurbiprofen compared with conventional treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901022-6

Leukotrienes in ulcerative colitis: results of a multicenter trial of a leukotriene biosynthesis inhibitor, MK-591.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901022-6

Cytokines in intestinal inflammation: pathophysiological and clinical considerations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901022-6

Induction of interleukin-6 release by interleukin-1 in rat anterior pituitary cells in vitro: evidence for an eicosanoid-dependent mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901022-6

Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901022-6

Inhibition of platelet thromboxane synthetase by sulfasalazine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901022-6

Highly selective inhibitors of thromboxane synthetase. 2. Pyridine derivatives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901022-6

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901022-6

Prostaglandin protection of rat colonic mucosa from damage induced by ethanol.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901022-6

Vasoconstriction with thromboxane A2 induces ulceration of the gastric mucosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901022-6

Treatment with 16,16'-dimethyl prostaglandin E2 before and after induction of colitis with trinitrobenzenesulfonic acid in rats decreases inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901022-6

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0014-2999(01)01022-6

1 reference

25 November 2017

1 reference